Imugene (ASX:IMU) received a notice of allowance from the Chinese patent office for City of Hope's patent application for the CD19-expressing oncolytic virus, onCARlytics, according to a Wednesday Australian bourse filing.
The patent protects the method of composition and method of use of onCARlytics through to 2038.
OnCARlytics is exclusively licensed to Imugene and is a CD19-expressing oncolytic virus that enters solid tumor cells, forcing them to express the CD19 protein on the cell surface, presenting a target for CD19-targeting therapies.
Its OASIS dose escalation trial of onCARlytics is being conducted at up to ten sites in the US, with up to around 40 patients proposed to take part.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。